391,529 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by Nicholas Investment Partners LP

Nicholas Investment Partners LP purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 391,529 shares of the company’s stock, valued at approximately $19,870,000. Enliven Therapeutics makes up approximately 1.1% of Nicholas Investment Partners LP’s portfolio, making the stock its 22nd largest position.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. increased its position in shares of Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after acquiring an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the period. KBC Group NV purchased a new stake in shares of Enliven Therapeutics in the 1st quarter valued at approximately $38,000. Finally, Swiss National Bank boosted its stake in Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. The trade was a 13.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director directly owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 196,849 shares of company stock valued at $11,344,257. 3.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Guggenheim dropped their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. JonesTrading raised their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 target price on the stock. Finally, William Blair started coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Enliven Therapeutics Stock Up 2.2%

Shares of Enliven Therapeutics stock opened at $61.15 on Tuesday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32. The stock has a 50 day moving average price of $53.36 and a two-hundred day moving average price of $42.30. The stock has a market capitalization of $4.48 billion, a P/E ratio of -36.62 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.